[18F]fluoro-PEG-folate PET/CT imaging in patients with epithelial ovarian cancer - [18F]fluoro-PEG-folate PET/CT imaging in epithelial ovarian cancer

eids Universitair Medisch Centrum0 个研究点目标入组 15 人开始时间: 待定最近更新: 2024年4月15日

适应症

试验速览

暂无简介。

•Patients with radiologically FIGO stage IIIB/IIIC EOC based on the conventional
•CT scan who are
•scheduled to undergo primary cytoreductive surgery and
•a) in whom EOC is histologically proven, or
•b) in whom EOC is cytologically suspected and a serum CA125/CEA ratio > 25 is
•treated with neoadjuvant chemotherapy (NACT) and are scheduled to undergo
•interval cytoreductive surgery and
•a) in whom EOC is histologically proven, or
•b) in whom EOC is cytologically suspected and a serum CA125/CEA ratio > 25 was
•found before NACT
•c) and with radiologically FIGO stage IIIB/IIIC EOC based on the response
•evaluation CT scan after NACT

•1. Women younger than 30 years of age (in accordance with the guidelines of the
•Netherlands Commission on Radiation Dosimetry, as the total radiation dose will
•be 7.2 mSv)
•2. Patients who previously underwent primary laparotomy and in whom complete or
•optimal cytoreduction was not considered feasible.
•3. Contraindication for PET (pregnancy, lactating or severe claustrophobia)
•4. Thrombocytopenia (platelet count < 100 x 10^9/L) and/or INR > 2
•5. Impaired renal function (defined as eGFR < 50 mL/1.73 m2)
•6. Impaired liver function (ALT, AST or total bilirubin > 3x upper limit of
•7. Clinically significant abnormalities on ECG and/or clinically laboratory
•8. Inability to tolerate lying supine for the duration of a PET/CT examination
•(~110 minutes)
•9. Patients with concomitant malignancy (except basal cell carcinoma of the
•skin) or any condition that in the opinion of the investigators could
•potentially jeopardize the health status of the patient
•10. Patients not able to comply with the study procedures
•11. Patients who did not give informed consent

发起方